Efficacy and safety of a new drug formulation, amoxicillin-clavulanate-cineole, for adult lower respiratory tract infections: a nationwide observational study in Morocco
Authors:
- Youness El AchhabYAYouness El Achhab
- the ORCA Study GroupTGthe ORCA Study Group
Open Access
- 30 May 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1549014
Abstract
Background: Lower respiratory tract infections (LRTIs) remain significant global health threats, causing substantial morbidity and mortality. The treatment landscape for LRTIs has evolved significantly, presenting increasing challenges due to rising antibiotic resistance and frequent treatment failures. This study aims to examine the real-life efficacy and safety of a new drug formulation, Olipen® (amoxicillin-clavulanate-cineole), in adult patients with LRTIs within the community setting.Methods: This observational, non-interventional study recruited 936 patients. Olipen® 500 mg (amoxicillin 500 mg, clavulanate 62.5 mg, cineole 100 mg) was administered as two sachets, three times daily, for 7–14 days, as per clinical practice guidelines. The primary outcome focused on the clinical recovery and safety as a secondary outcome.Results: A total of 936 patients were enrolled in the study at the national level. Nearly all patients (94.9%) achieved clinical recovery. Therapeutic failure was reported in 26 patients (2.8%), while the outcome remained undetermined for 22 patients (2.3%). After 3–4 days of treatment, 57.8% of patients were symptom-free. Radiologically, 81% of patients showed improvement during follow-up. Treatment effectiveness is not affected patient characteristics, whereas chronic cough and dyspnea may hinder clinical recovery in pa-tients with LTRIs. Olipen® was well tolerated, with most of the adverse events reported were considered non-serious and most of them were resolved (87.5%).Conclusion: Olipen® was found to be effective and well tolerated in adults with acute exacerbation of chronic bronchitis/COPD, community-acquired pneumonia or superinfection as well as adult patients with pathological lung.Keywords
This publication has 36 references indexed in Scilit:
- 1,8-Cineole: a review of source, biological activities, and applicationJournal of Asian Natural Products Research, 2020
- Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usageClinical Microbiology and Infection, 2020
- Sociodemographic, climatic variability and lower respiratory tract infections: a systematic literature reviewInternational Journal of Biometeorology, 2019
- Classification of Cough as a Symptom in Adults and Management AlgorithmsChest, 2018
- The respiratory microbiome and respiratory infectionsJournal of Infection, 2017
- An update on the pharmacotherapeutic management of lower respiratory tract infectionsExpert Opinion on Pharmacotherapy, 2017
- Pneumonia Recovery; Discrepancies in Perspectives of the Radiologist, Physician and PatientJournal of General Internal Medicine, 2009
- The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adultsInternational Journal of Antimicrobial Agents, 2007
- The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infectionsInternational Journal of Antimicrobial Agents, 2007
- Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trialRespiratory Medicine, 2003